Recent advances in autoantibody-mediated pain.

Authors

Adham Farah, John M Dawes

Published in

Current opinion in supportive and palliative care. Jul 07, 2026. Epub Jul 07, 2026.

Abstract

Recent studies increasingly support a role for autoantibodies in selected chronic pain disorders. This review examines current evidence linking autoantibodies to nociceptive sensitisation and neuroimmune dysfunction across these conditions.
Experimental and clinical evidence links autoantibodies to altered neuronal excitability, neuroimmune activation, and pain hypersensitivity, particularly within the dorsal root ganglion and spinal sensory circuits. Emerging work further suggests that pathogenicity and treatment responsiveness depend on factors beyond antibody specificity alone, including tissue injury, inflammatory context, and downstream immune signalling mechanisms.
Autoimmune pain disorders appear to comprise biologically heterogeneous neuroimmune syndromes in which dorsal root ganglia and anatomically connected sensory pathways emerge as recurring sites of sensitisation. Pathogenicity depends not only on antibody specificity but also on tissue context and downstream neuroimmune mechanisms, supporting the development of more targeted and mechanism-based therapeutic approaches.

PMID:
42411311
Bibliographic data and abstract were imported from PubMed on 07 Jul 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.